Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026)
Argenx Se's (ARGX) quarterly Net Income towards Common Stockholders came in at $472.0 million in Q2 2026, up 92.37% YoY from $245.4 million in Q2 2025, and up 28.96% on a QoQ basis from $366.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Net Income towards Common Stockholders data on file, last reported at $472.0 million in Q2 2026.
- Quarterly Net Income towards Common Stockholders rose 92.37% year-over-year to $472.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 34.01% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
- Net Income towards Common Stockholders advanced to $472.0 million in Q2 2026, from $366.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $774.2 million in Q4 2024 to a low of -$235.0 million in Q3 2022.
- A 5-year average of $183.8 million and a median of $134.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders slumped 313.35% — and 2025, when it jumped 744.14%.
- Tracing ARGX's Net Income towards Common Stockholders over 5 years: stood at $38.6 million in 2022, then surged by 156.84% to $99.2 million in 2023, then jumped by 680.62% to $774.2 million in 2024, then sank by 31.16% to $532.9 million in 2025, then dropped by 11.44% to $472.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $472.0 million (Q2 2026), $366.0 million (Q1 2026), and $532.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.68 Bn | 131.82 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.68 Bn | 77.68 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.67 Bn | 58.48 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.02 Bn | 51.88 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.83 Bn | 43.83 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.97 Bn | 34.87 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.23 Bn | 31.93 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.56 Bn | 27.72 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn | 585.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 472.00 Mn |
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 344.26 Mn |
| Jun 30, 2025 | 245.36 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 774.16 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | -28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | -235.04 Mn |
| Jun 30, 2022 | -208.75 Mn |
| Mar 31, 2022 | -227.19 Mn |
| Dec 31, 2021 | -237.82 Mn |
| Sep 30, 2021 | -233.61 Mn |